Modafinil Orion (Modafinil)

Modafinil acts on central nervous system pathways that regulate wakefulness.

• Narcolepsy: reduces daytime sleep attacks and improves alertness.
• Obstructive sleep apnea‑related excessive daytime sleepiness: lessens residual sleepiness despite optimal apnea therapy.
• Shift work sleep disorder: helps maintain alertness during scheduled work hours.

• Modafinil inhibits the neuronal reuptake of dopamine, leading to increased extracellular dopamine concentrations. It also influences orexinergic, histaminergic and noradrenergic neurotransmission, enhancing cortical activation and promoting wakefulness without directly stimulating adrenergic receptors. These actions are mediated through modulation of the hypothalamic arousal system and increased thalamocortical activity, supporting sustained vigilance.

Modafinil may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Headache: mild to moderate intensity, often transient.
• Nausea: occasional gastrointestinal upset, may improve with food.
• Insomnia: difficulty falling or staying asleep, especially if taken late.
• Dry mouth: reduced salivation causing throat discomfort.

Serious or Rare Side Effects

• Stevens‑Johnson syndrome: severe skin reaction with blistering and detachment.
• Cardiovascular events: chest pain, arrhythmia, or hypertension requiring evaluation.
• Psychiatric disturbances: hallucinations, severe mood changes, or psychosis.
• Liver injury: elevated liver enzymes, hepatitis, or jaundice.

When prescribing Modafinil Orion, clinicians should consider several precautionary measures to ensure safe use.

• Assess cardiovascular history: evaluate for hypertension, arrhythmias, or ischemic heart disease.
• Review psychiatric status: monitor for anxiety, depression, or history of psychosis.
• Consider hepatic function: adjust use in patients with liver impairment.
• Avoid use in uncontrolled sleep apnea: may mask residual sleepiness.
• Counsel on driving: advise patients to assess alertness before operating machinery.
• Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Modafinil can affect the pharmacokinetics of several medicines, necessitating careful review of concomitant therapies.

Major Interactions (Avoid)

• CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin): may markedly reduce modafinil exposure.
• Hormonal contraceptives: reduced efficacy, consider alternative or additional barrier methods.
• Antidepressants (e.g., fluvoxamine): increased risk of serotonin syndrome.

Moderate Interactions (Monitor Closely)

• CYP2C19 inhibitors (e.g., fluoxetine, omeprazole): may increase modafinil levels.
• Anticoagulants (e.g., warfarin): potential alteration of INR, monitor coagulation.
• Antihypertensives: possible reduction in blood pressure effect, observe blood pressure.